Lineage Cell Therapeutics (LCTX) Tops Q4 EPS by 2c

Lineage Cell Therapeutics (NYSE: LCTX) reported Q4 EPS of $0.02. Revenue for the quarter came in at $2.9 million.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Taysha Gene Therapies (TSHA) PT Raised to $10 at BofA Securities
• Rubio to visit Gulf states amid Iran deal concerns